Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability and Food Effect of Orally Administrated Octreotide Acetate Tablets (T25) vs MYCAPSSA in Healthy Participants
NCT07663318Phase 1Completed
- Sponsor
- Triastek
- Start
- Jun 2026
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of octreotide in acromegaly (3 arms), sponsored by Triastek. Primary endpoint: Relative Bioavailability. Started Jun 2026; status: completed.
02
Drugs
octreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT07663318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07663318.